Cheng Andrew's Form 4 filing
Akero Therapeutics, Inc. (AKRO) · filed Jan 11, 2022
- Accession no.
- 0001104659-22-003317
- Filed
- Jan 11, 2022
- Trade date
- Jan 10, 2021-Jan 10, 2022
- Filing delay
- 366 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $195.5K. It was filed 366 days after the trade, past the 2-business-day deadline.
This filing was later replaced by the amendment 0001104659-22-029565 (Mar 2, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cheng AndrewCIK 0001778307 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 10, 2022 | Common Stock | MOption exerciseAcquired | +10,000 | $0.62 | +$6,200 | 308,996 | Direct | |
| Jan 10, 2021 | Common Stock | SSaleDisposed | −10,000 | $19.55F2 | −$195,500 | 298,996 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 10, 2022 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 320,868 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.225 to $19.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Referenced by the price of 1 transaction in Table I.